Cambridge Cognition Holdings Plc (LSE:COG) has spent 2026 rebuilding its Balance Sheet and pushing its CANTAB cognitive-testing software beyond the pharmaceutical Clinical Trials that generate almost all of its revenue. A £2.6m Equity raise at 35p closed in July, Debt has been repaid, and a trading update on 27 July 2026 reported first-half Revenue up 16% with the Board "confident" of meeting full-year market expectations.
Yet the shares trade at around 31p, below the placing price, valuing the Cambridge-based Business at roughly £16.7m. The question for investors is whether the 2025 recovery in order intake converts into sustained growth, and whether new healthcare and consumer wellness initiatives, including a 45,000-participant study with smart-ring maker Oura, can become a second revenue engine.
H1 2026 trading update: revenue up 16%, debt cleared
On 27 July 2026 Cambridge Cognition reported unaudited revenue of £5.0m for the six months to 30 June 2026, up 16% from £4.3m a year earlier. The adjusted EBITDA loss narrowed to £0.3m from £0.4m and Operating Cash Flow was positive. Cash at 30 June 2026 was £0.6m, net cash £0.4m, and borrowings had fallen to £0.2m. After the July placing the Facility was "fully repaid, leaving the Company debt free".
New sales orders were £6.0m, down from £6.9m, and the order book at 30 June 2026 was £16.1m against £16.4m a year earlier; a further £1.0m contract was signed just after period end. Contracted full-year revenue is stated at not less than £10.0m, and the Board "remains confident in meeting market expectations for the full year", understood to be revenue of £11.35m and an adjusted loss before tax of £1.25m. First healthcare and consumer wellness revenue of £0.1m was also recorded.
Chief executive Rob Baker said: "This has been an important six months for the Company. We are strengthening our core business, have cleared our debt facility and are making exciting strategic moves."
The funding was announced on 23 June 2026: a placing, subscription and retail offer at 35p, with no discount to the previous close, raising approximately £2.6m gross through 7,407,628 new shares admitted on 13 July 2026. Existing Shareholder Brett Gordon lifted his stake to 17.9% and every director participated. Proceeds fund CE marking and US FDA 510(k) clearance, paediatric normative datasets, speech recognition for Winterlight and working capital.
Business overview: the CANTAB franchise
Cambridge Cognition develops digital cognitive assessments measuring memory, attention and executive function. Its CANTAB touchscreen battery has been in use for more than 30 years, and the Winterlight voice-analysis technology adds speech-based measures.
Revenue is dominated by clinical studies, where pharmaceutical sponsors license the software and buy services for trials in neurological and psychiatric conditions. In FY2025 clinical studies generated £8.4m of the £9.4m total, academic research £0.8m, professional healthcare just £0.05m and royalties £0.15m.
The strategic shift is towards CANTAB Pathway, a tiered set of shorter assessments aimed at healthcare providers and consumer wellness platforms. A commercialisation agreement for India was signed with Ivory in February 2026, a pilot with a major private European healthcare organisation is under way, and the Oura collaboration launched on 28 May 2026 will run an IRB-approved brain health study across up to 45,000 Oura members through 2026. The company also holds a 20% stake in Monument Therapeutics, whose MT1988 candidate entered a 150-participant, FNIH-funded study in March 2026.
FY2025 results: revenue down 10%, orders up 73%, going-concern caveat
The audited results for the year to 31 December 2025, published on 13 April 2026, showed revenue of £9.4m, down 10% from £10.3m in FY2024. Gross Margin was 75%. The adjusted EBITDA loss widened to £0.5m from £0.04m, the operating loss was £1.24m (FY2024: £1.17m) and the loss before tax narrowed to £1.57m from £1.71m. Basic loss per share was 3.9p (FY2024: 4.6p). No Dividend is paid.
The commercial picture was stronger. New sales orders rose 73% to £12.8m and the closing order book was £16.5m, up 21%. Year-end cash was £1.13m with net cash of £0.27m, against net debt of £0.6m a year earlier.
The accounts carried an important caveat. The directors concluded that reliance on cash from new orders, and the potential need for cost savings or a fundraise, "represents a material uncertainty that may cast significant doubt upon the Group's ability to continue as a going concern". The auditor included an emphasis of matter without qualifying its report, and a reverse stress test showed cash falling to nil in the third quarter of 2026 under a severe drop in orders. The £2.6m raise addressed the immediate pressure, but the £0.6m cash balance at 30 June 2026 was struck before the placing proceeds arrived.
What could drive the stock next?
The most immediate catalyst is the interim results for the six months to 30 June 2026, published last year at the end of August, which should show the post-placing cash position. Second-half order intake matters more: with contracted revenue of at least £10.0m against consensus of £11.35m, further wins are needed to close the gap.
Progress on CANTAB Pathway is the longer-term driver. Evidence that the Oura study generates paid usage, that the Ivory Partnership produces revenue, or that the European healthcare pilot converts into a commercial contract would validate the Diversification case. CE marking and FDA 510(k) milestones would open professional healthcare markets. MT1988 trial data could also change the value ascribed to the Monument stake, carried at £1.8m at June 2025.
Risks investors should watch
Liquidity remains the primary risk. Even after the raise, cash resources are modest relative to an adjusted loss before tax forecast at £1.25m for FY2026, and the going-concern language in the FY2025 accounts shows how dependent the business is on the timing of order conversion. Further dilution cannot be ruled out.
Order lumpiness is a second concern: first-half 2026 orders were 13% lower year on year, so the 2025 recovery is not yet an established trend. Concentration in pharmaceutical clinical trials leaves the company exposed to sponsor budget cycles and trial cancellations. The consumer and healthcare push is unproven, and the Oura and Ivory agreements have no disclosed financial terms. With a Market Capitalisation under £20m and one shareholder holding nearly 18%, the shares are Illiquid and can move sharply on small volumes.
Outlook
Cambridge Cognition enters the second half of 2026 in better shape than it started the year: debt free, with a £16m order book and management endorsing consensus revenue of £11.35m, around 21% above FY2025. Interim results and second-half contract news will show whether that is on track.
The larger prize is turning CANTAB Pathway from a £0.1m line item into a meaningful business, and the Oura study is the most visible test of that ambition. Investors should weigh operational progress against the still-slender cash position and a history of losses; the interim statement and any update on healthcare revenues will indicate whether the July placing marks a turning point or merely a pause.






Please wait processing your request...